What question did this study set out to answer?

The aim is to evaluate the safety and tolerability of BAY 94-8862 compared to spironolactone in patients with chronic heart failure and kidney disease.

May 27, 2013European Heart JournalOpen Access

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the safety and tolerability of BAY 94-8862 compared to spironolactone in patients with chronic heart failure and kidney disease.
Randomized, double-blind trial comparing BAY 94-8862 (5-10 mg/day) with spironolactone (25 or 50 mg/day).
Participants included patients with HFrEF and moderate chronic kidney disease.
Assessments focused on biomarkers of haemodynamic stress, hyperkalaemia, and worsening renal function.
BAY 94-8862 was at least as effective as spironolactone in decreasing biomarkers of haemodynamic stress.
Incidences of hyperkalaemia and worsening renal function were lower with BAY 94-8862.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows BAY 94-8862 decreases biomarkers in chronic heart failure and kidney disease, suggesting it may be safer than existing treatments.

Cite This Study

Pitt et al. (2013) studied this question.

synapsesocial.com/papers/69d5708e75589c71d767dd14 https://doi.org/10.1093/eurheartj/eht187

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows BAY 94-8862 decreases biomarkers in chronic heart failure and kidney disease, suggesting it may be safer than existing treatments.

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Key Points

Discussion

Implication

Cite This Study

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider